Patents by Inventor Ziping QI
Ziping QI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220064117Abstract: Disclosed are a kinase inhibitor and a pharmaceutical composition comprising the kinase inhibitor. The kinase inhibitor comprises a compound as represented by formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite, or prodrug thereof. The compound and composition above can inhibit wild-type KIT and/or mutant KIT tyrosine kinase activity and treat, prevent, or alleviate diseases, disorders, or conditions associated with wild-type KIT and/or mutant KIT kinase activity.Type: ApplicationFiled: December 20, 2018Publication date: March 3, 2022Applicant: Tarapeutics Science Inc.Inventors: Jing LIU, Qingsong LIU, Yun WU, Beilei WANG, ZiPing QI, Fengming ZOU, Qingwang LIU, Wenchao WANG, Cheng CHEN, Junjie WANG, Li WANG
-
Publication number: 20220024931Abstract: The present application relates to a compound serving as a selective PI3K? kinase inhibitor, comprising the compound shown in formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof, wherein X, R1, R2, R3, R4, R5 and R6 are as defined in the description. The present application also relates to a method for using the kinase inhibitor to inhibit PI3K? kinase activity or to treat or prevent diseases or conditions associated with tyrosine kinase activity of PI3K?, as well as a use thereof.Type: ApplicationFiled: December 12, 2018Publication date: January 27, 2022Applicant: TARAPEUTICS SCIENCE INC.Inventors: Qingsong LIU, Jing LIU, Xiaofei LIANG, Feng LI, Ziping QI, Zongru JIANG, Qingwang LIU, Kailin YU, Zhenquan HU, Beilei WANG, Li WANG
-
Publication number: 20220002287Abstract: The present invention relates to a kinase inhibitor, comprising a compound represented by formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof. The present invention further relates to pharmaceutical compositions comprising the kinase inhibitor, as well as to using said compounds and compositions to inhibit cKIT (especially mutant cKIT/T670I), FLT3 (comprising mutant FLT3-ITD), PDGF, PDGF, and/or VEGFR2 kinase activity in cells or a subject, and/or to a use and method for preventing or treating disorders related to cKIT (especially mutant cKIT/T670I), FLT3 (comprising mutant FLT3-ITD), PDGF, PDGF, and/or VEGFR2 activity in a subject.Type: ApplicationFiled: November 12, 2018Publication date: January 6, 2022Applicant: Tarapeutics Science Inc.Inventors: Jing LIU, Qingsong LIU, Xuesong LIU, Beilei WANG, Cheng CHEN, Ziping QI, Wenchao WANG, Junjie WANG, Zongru JIANG, Wenliang WANG, Shuang QI, Li WANG
-
Publication number: 20210346406Abstract: Disclosed is a kinase inhibitor, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite, or prodrug thereof. Also disclosed are a pharmaceutical composition comprising the kinase inhibitor and uses and methods for inhibiting the activity of one or more tyrosine kinases selected from MST1 and a mutant thereof in a cell or subject and for preventing or treating a disease related to MST1 or a mutant thereof in a subject by using the compound or composition.Type: ApplicationFiled: October 9, 2019Publication date: November 11, 2021Applicant: HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCESInventors: Qingsong LIU, Jing LIU, Yun WU, Wenliang WANG, Beilei WANG, ZiPing QI, Junjie WANG, Wenchao WANG, Shuang QI, Li WANG
-
Patent number: 10975082Abstract: The present invention provides a novel inhibitor of FLT3 kinase, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, ester, acid, metabolite or prodrug thereof. The present invention also provides a pharmaceutical composition comprising the compound of formula (I), as well as the use and method for preventing or treating FLT3-related conditions, especially conditions related to mutant FLT3 kinase (particularly, FLT3/ITD mutant kinase).Type: GrantFiled: June 5, 2017Date of Patent: April 13, 2021Assignee: PRECEDO PHARMACEUTICALS CO., LTDInventors: Qingsong Liu, Jing Liu, Xixiang Li, Aoli Wang, Ziping Qi, Hong Wu, Jiaxin Wu, Wenchao Wang, Chen Hu, Cheng Chen, Li Wang, Beilei Wang
-
Patent number: 10793543Abstract: The present invention provides a compound represented by formula (I), or a pharmaceutically acceptable salt, a solvate, an ester, an acid, a metabolite or a prodrug thereof. The compound itself in the present invention or in combination with at least one therapeutic agent can be used for preventing or treating diseases, disorders or symptoms caused by the adjustment of the activity of tyrosine kinase C-KIT, or affected by the activity of the tyrosine kinase C-KIT or involving in the activity of the tyrosine kinase C-KIT, especially cancers or other cell proliferation diseases.Type: GrantFiled: March 28, 2017Date of Patent: October 6, 2020Assignees: PRECEDO PHARMACEUTICALS CO., LTD, HEFEI GRACEVO BIO-MEDICINE CO., LTDInventors: Qingsong Liu, Jing Liu, Qiang Wang, Beilei Wang, Feiyang Liu, Shuang Qi, Ziping Qi, Fengming Zou, Cheng Chen, Wenchao Wang, Chen Hu, Xiaochuan Liu, Wei Wang, Aoli Wang, Li Wang, Zhenquan Hu, Tao Ren
-
Patent number: 10781214Abstract: The present application provides a compound of Formula (I) as an inhibitor against wild-type EGFR and/or mutant EGFR, which may be used for treating human non-small cell lung cancer individually or in combination with other therapeutic agent(s). The compound of Formula (I) of the present application may be used for treating patients of drug-resistant human non-small cell lung cancer harboring wild-type EGFR and/or EGFR T790M mutation and/or EGFR L858R mutation and/or EGFR delE746_A750 mutation.Type: GrantFiled: December 27, 2016Date of Patent: September 22, 2020Assignee: PRECEDO PHARMACEUTICALS CO., LTD.Inventors: Qingsong Liu, Jing Liu, Xixiang Li, Aoli Wang, Hong Wu, Kailin Yu, Chen Hu, Wenchao Wang, Cheng Chen, Fengming Zou, Ziping Qi, Li Wang, Beilei Wang
-
Publication number: 20200010471Abstract: The present invention provides a novel inhibitor of FLT3 kinase, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, ester, acid, metabolite or prodrug thereof. The present invention also provides a pharmaceutical composition comprising the compound of formula (I), as well as the use and method for preventing or treating FLT3-related conditions, especially conditions related to mutant FLT3 kinase (particularly, FLT3/ITD mutant kinase).Type: ApplicationFiled: June 5, 2017Publication date: January 9, 2020Applicant: PRECEDO PHARMACEUTICALS CO., LTDInventors: Qingsong LIU, Jing LIU, Xixiang LI, Aoli WANG, Ziping QI, Hong WU, Jiaxin WU, Wenchao WANG, Chen HU, Cheng CHEN, Li WANG, Beilei WANG
-
Patent number: 10350210Abstract: The present application provides a compound of formula I, which is a EGFR and ALK dual inhibitor and can be used alone or in combination with other therapeutic agents to treat diseases such as non-small cell lung cancer. The compounds of the present application are useful in the treatment of diseases carrying the EGFR wild-type gene, or carrying the EGFR T790M mutant gene and/or the EGFR L858R mutant gene and/or the EGFR delE746_A750 mutant gene, or in the treatment of diseases carrying the ALK wild-type gene, ALK F1174L mutant gene and/or ALK F1196M gene and/or EML4-ALK mutant gene and/or NPM-ALK mutant gene, and can be used in the first-line treatment of anaplastic lymphoma kinase (ALK) positive late-stage non-small cell Lung cancer.Type: GrantFiled: December 15, 2016Date of Patent: July 16, 2019Assignee: PRECEDO PHARMACEUTICALS CO., LTDInventors: Jing Liu, Qingsong Liu, Taoshan Jiang, Aoli Wang, Jiaxin Wu, Hong Wu, Ziping Qi, Yongfei Chen, Fengming Zou, Wenchao Wang, Zheng Zhao, Li Wang, Beilei Wang
-
Publication number: 20190084960Abstract: The present invention provides a compound represented by formula (I), or a pharmaceutically acceptable salt, a solvate, an ester, an acid, a metabolite or a prodrug thereof. The compound itself in the present invention or in combination with at least one therapeutic agent can be used for preventing or treating diseases, disorders or symptoms caused by the adjustment of the activity of tyrosine kinase C-KIT, or affected by the activity of the tyrosine kinase C-KIT or involving in the activity of the tyrosine kinase C-KIT, especially cancers or other cell proliferation diseases.Type: ApplicationFiled: March 28, 2017Publication date: March 21, 2019Applicants: PRECEDO PHARMACEUTICALS CO., LTD, HEFEI GRACEVO BIO-MEDICINE CO., LTDInventors: Qingsong LIU, Jing LIU, Qiang WANG, Beilei WANG, Feiyang LIU, Shuang QI, Ziping QI, Fengming ZOU, Cheng CHEN, Wenchao WANG, Chen HU, Xiaochuan LIU, Wei WANG, Aoli WANG, Li WANG, Zhenquan HU, Tao REN
-
Publication number: 20190010159Abstract: The present application provides a compound of Formula (I) as an inhibitor against wild-type EGFR and/or mutant EGFR, which may be used for treating human non-small cell lung cancer individually or in combination with other therapeutic agent(s). The compound of Formula (I) of the present application may be used for treating patients of drug-resistant human non-small cell lung cancer harboring wild-type EGFR and/or EGFR T790M mutation and/or EGFR L858R mutation and/or EGFR delE746_A750 mutation.Type: ApplicationFiled: December 27, 2016Publication date: January 10, 2019Applicant: PRECEDO PHARMACEUTICALS CO., LTDInventors: Qingsong LIU, Jing LIU, Xixiang LI, Aoli WANG, Hong WU, Kailin YU, Chen HU, Wenchao WANG, Cheng CHEN, Fengming ZOU, Ziping QI, Li WANG, Beilei WANG
-
Publication number: 20180369242Abstract: The present application provides a compound of formula I, which is a EGFR and ALK dual inhibitor and can be used alone or in combination with other therapeutic agents to treat diseases such as non-small cell lung cancer. The compounds of the present application are useful in the treatment of diseases carrying the EGFR wild-type gene, or carrying the EGFR T790M mutant gene and/or the EGFR L858R mutant gene and/or the EGFR delE746_A750 mutant gene, or in the treatment of diseases carrying the ALK wild-type gene, ALK F1174L mutant gene and/or ALK F1196M gene and/or EML4-ALK mutant gene and/or NPM-ALK mutant gene, and can be used in the first-line treatment of anaplastic lymphoma kinase (ALK) positive late-stage non-small cell Lung cancer.Type: ApplicationFiled: December 15, 2016Publication date: December 27, 2018Applicant: PRECEDO PHARMACEUTICALS CO., LTDInventors: Jing LIU, Qingsong LIU, Taoshan JIANG, Aoli WANG, Jiaxin WU, Hong WU, Ziping QI, Yongfei CHEN, Fengming ZOU, Wenchao WANG, Zheng ZHAO, Li WANG, Beilei WANG